ACTG (AIDS Clinical Trials Group) 384

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

1997 • 2,670 citations

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

1976 • 2,290 citations

Fundamentals of Clinical Trials

2015 • 2,168 citations

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

1997 • 1,912 citations

The statistical analysis of failure time data

1981 • 1,241 citations

Modelling Survival Data in Medical Research.

1994 • 1,054 citations

Antiretroviral Therapy in Adults

2000 • 1,045 citations

Planning of Experiments

1958 • 1,040 citations

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

1999 • 1,008 citations

Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models

1999 • 944 citations

Fundamentals of Clinical Trials

1998 • 867 citations

A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients

1998 • 777 citations

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

2000 • 332 citations

Ranking Procedures for Arbitrarily Restricted Observation

1967 • 305 citations

Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection

1996 • 293 citations

Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection

1998 • 243 citations

Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies

1996 • 214 citations

Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients

1998 • 199 citations

Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors

1998 • 197 citations

Modelling Survival Data in Medical Research.

1995 • 187 citations

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients

1996 • 183 citations

Antiretroviral Therapy in Adults

1996 • 142 citations

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

1999 • 115 citations

Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection

1999 • 80 citations

Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection

1996 • 75 citations

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine

1999 • 69 citations

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations

1999 • 52 citations

AIDS clinical trials

1995 • 43 citations

Efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-Drug Combinations of These Agents in Persons With HIV Disease With CD4 Counts of 100 to 500 cells/mm3 (ACTG 261)

1999 • 42 citations

Failure of HIV-1 Protease Inhibitors to Fully Suppress Viral Replication

1999 • 25 citations

Trial design in the era of highly effective antiviral drug combinations for HIV infection.

1998 • 15 citations

Efficient Trial Designs for Studying Combination Antiretroviral Treatments in Patients with Various Resistance Profiles

1998 • 5 citations

Cited By (0)

Loading...